# Overview: Peptides and the Schedule II Debate

Canonical source: https://retacompare.com/research/peptides-schedule-ii-overview-160

Schedule II & RFK · 2026-01-14


    A number of peptides and peptide-like substances have long been caught up in DEA scheduling or state-level scheduling debates. Anabolic peptide hormones and growth hormone secretagogues in particular have faced state-by-state scheduling variation. With Robert F. Kennedy Jr. confirmed as Secretary of Health and Human Services in early 2025, federal policy discussion about rescheduling certain substances — including several peptide-category compounds — moved from the margins to the center of health policy. Throughout 2025 and into 2026, formal and informal processes have examined whether several peptides and related substances should come off restrictive scheduling lists, with implications for research, clinical use, and commercial availability.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources